deferasirox has been researched along with Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chew, SH; Misawa, N; Nagai, H; Okazaki, Y; Toyokuni, S; Yasui, H | 1 |
| Toyokuni, S | 1 |
1 review(s) available for deferasirox and Mesothelioma
| Article | Year |
|---|---|
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
Topics: Adsorption; Animals; Asbestos; Asbestosis; Benzoates; Carcinogens, Environmental; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Deferasirox; Ferric Compounds; Ferric Oxide, Saccharated; Genes, p16; Glucaric Acid; Humans; Iron Chelating Agents; Iron Overload; Japan; Kidney Neoplasms; Male; Mesothelioma; Mineral Fibers; Peritoneal Neoplasms; Phlebotomy; Pleural Neoplasms; Rats; Triazoles | 2014 |
1 other study(ies) available for deferasirox and Mesothelioma
| Article | Year |
|---|---|
Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats.
Topics: Animals; Asbestos, Crocidolite; Benzoates; Cell Transformation, Neoplastic; Deferasirox; Epithelial-Mesenchymal Transition; Female; Iron; Iron Chelating Agents; Male; Mesothelioma; Phlebotomy; Rats; Spleen; Triazoles | 2013 |